Fig. 6. Response of chemo-naïve and chemo-resistant human high-grade serous ovarian cancer to WEHI-7326 in a PDX mouse model.

PDX models of HG-SOC in recipient female mice: tumor growth curves and corresponding Kaplan–Meier survival plots for (a, b) chemo-naïve PDX tumor line 134056 (BRCA2 mutant), (c, d) the chemo-naïve PDX tumor line 134183 (Rad51C methylated), (e, f) 134197 (genotype unknown, platinum resistant PDX) and (g, h) 134036 (C5 PDX, platinum refractory). Each model was treated for 6 weeks with either vehicle or WEHI-7326 (20 mg/kg; twice a week) via tail vein injection, followed by an observational period. Ethical endpoint was tumor size >700 mm³; when mice had to be culled not due to tumor size (illness, weight loss or found dead) data from these mice were removed from the experiment. Displayed are p-values compared to vehicle obtained through Log-rank (Mantel–Cox) test.